Impax Laboratories (IPXL) Upgraded at BidaskClub

Impax Laboratories (NASDAQ:IPXL) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday.

IPXL has been the subject of several other reports. UBS Group upped their price objective on Impax Laboratories from $12.00 to $16.00 and gave the stock a “sell” rating in a research note on Monday, October 30th. Cantor Fitzgerald set a $35.00 price objective on Impax Laboratories and gave the stock a “buy” rating in a research note on Friday, December 15th. Canaccord Genuity set a $19.00 price objective on Impax Laboratories and gave the stock a “hold” rating in a research note on Tuesday, October 17th. Leerink Swann began coverage on Impax Laboratories in a research note on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 price objective for the company. Finally, Zacks Investment Research lowered Impax Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the company’s stock. Impax Laboratories has an average rating of “Hold” and a consensus price target of $19.62.

Impax Laboratories (IPXL) traded down $0.23 during trading hours on Thursday, hitting $19.53. The stock had a trading volume of 806,563 shares, compared to its average volume of 963,297. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32. The stock has a market cap of $1,447.08, a price-to-earnings ratio of -3.12, a price-to-earnings-growth ratio of 0.97 and a beta of 1.11. Impax Laboratories has a 52-week low of $7.75 and a 52-week high of $25.70.

A number of hedge funds have recently modified their holdings of the business. TCW Group Inc. increased its stake in Impax Laboratories by 3,904.5% in the 4th quarter. TCW Group Inc. now owns 1,987,950 shares of the specialty pharmaceutical company’s stock worth $33,099,000 after buying an additional 1,938,307 shares in the last quarter. Rhumbline Advisers increased its stake in Impax Laboratories by 14.0% in the 4th quarter. Rhumbline Advisers now owns 177,081 shares of the specialty pharmaceutical company’s stock worth $2,948,000 after buying an additional 21,775 shares in the last quarter. Arizona State Retirement System increased its stake in Impax Laboratories by 222.9% in the 4th quarter. Arizona State Retirement System now owns 124,564 shares of the specialty pharmaceutical company’s stock worth $2,074,000 after buying an additional 85,988 shares in the last quarter. Pinebridge Investments L.P. increased its stake in Impax Laboratories by 13.0% in the 4th quarter. Pinebridge Investments L.P. now owns 124,512 shares of the specialty pharmaceutical company’s stock worth $2,073,000 after buying an additional 14,297 shares in the last quarter. Finally, First Trust Advisors LP purchased a new stake in Impax Laboratories in the 4th quarter worth $1,150,000. Institutional investors and hedge funds own 91.54% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Impax Laboratories (IPXL) Upgraded at BidaskClub” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/11/impax-laboratories-ipxl-upgraded-at-bidaskclub.html.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply